Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) EBT (2020 - 2025)

Journey Medical's EBT history spans 6 years, with the latest figure at -$1.2 million for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 178.82% year-over-year to -$1.2 million, compared with a TTM value of -$11.4 million through Dec 2025, up 22.18%, and an annual FY2025 reading of -$11.4 million, up 22.18% over the prior year.
  • EBT for Q4 2025 was -$1.2 million at Journey Medical, up from -$2.3 million in the prior quarter.
  • The five-year high for EBT was $16.9 million in Q3 2023, with the low at -$15.3 million in Q2 2021.
  • Average EBT over 5 years is -$5.1 million, with a median of -$3.9 million recorded in 2025.
  • Year-over-year, EBT crashed 27063.46% in 2021 and then surged 267.67% in 2023.
  • Tracing DERM's EBT over 5 years: stood at -$13.4 million in 2021, then rose by 20.77% to -$10.6 million in 2022, then surged by 81.02% to -$2.0 million in 2023, then skyrocketed by 178.43% to $1.6 million in 2024, then tumbled by 178.82% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's EBT are -$1.2 million (Q4 2025), -$2.3 million (Q3 2025), and -$3.7 million (Q2 2025).